Cambridge Consultants Brings The 'Connected Patient' Concept To Life
Main Category: Respiratory / AsthmaArticle Date: 07 May 2009 - 3:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
Cambridge Consultants has unveiled technology to connect patients and their treatment devices, such as inhalers, with healthcare support professionals and a range of online applications. This 'connected patient' technology can allow healthcare specialists to monitor medication adherence, reduce long-term treatment costs, and improve patient access to, and interaction with, healthcare providers. Cambridge Consultants is displaying a Vena-enabled demonstration, implementing the standards selected by the Continua Health Alliance device, at the Respiratory Drug Delivery Europe 2009 (RDD Europe) conference in Lisbon on 19-22 May 2009.
"The idea behind the 'connected patient' is to enable seamless data transfer using wireless technologies, from patient monitoring or treatment devices to a patient's healthcare network - a physician's office or online medical support applications, for example - to encourage patients to follow their planned treatment regime," said David Blakey, Head of Drug Delivery at Cambridge Consultants. "Using connected medical devices to close the loop between a patient and their healthcare provider can facilitate increased compliance, enable better therapy results, and may ultimately reduce long-term treatment costs."
To illustrate its connected patient concept, Cambridge Consultants is demonstrating an inhaler concept for improving compliance at RDD (Europe). Enabled by the company's Vena wireless healthcare device platform, the system connects through a personal computer or smart phone to an online personal healthcare application, and can remind the patient to take their treatment and send compliance information to the relevant personal healthcare portal. Both patient and healthcare specialist can access the secure information to monitor progress and connect with one another.
Non-patient-specific data from a population of users can also be aggregated to provide medical researchers, insurance providers and even policy makers with information to better evaluate a therapy's efficacy, improve patient outcomes and lower costs. Pharmaceutical companies with new therapies in Phase IV trials can directly access usage data to demonstrate and document compliance, correlating ongoing use with improved outcomes.
Connecting the patient and their therapy with the broader healthcare community makes possible a number of other new and valuable applications that would support the patient and ensure proper monitoring and treatment. Michael Dunkley, Vice President at Cambridge Consultants' US office, explains, "Parents of children or carers caring for seniors can monitor compliance and be alerted if a therapy is not being followed correctly. Both patients and caregivers can also be directly rewarded with appropriate incentives for achieving increased compliance. Moreover, they can link into consumer Web 2.0 healthcare communities, perhaps sharing information or getting encouragement from others. The system can also enable remote monitoring to facilitate early detection of potential problems and lead to proactive intervention."
The wireless technology at the core of the connected patient concept is based on Cambridge Consultants' Vena wireless healthcare device platform, which implements the standards selected by the Continua Health Alliance to empower patients to manage health and wellness anytime, anywhere. It embeds the Bluetooth(TM) Health Device Profile (HDP) optimised for the secure transport of medical data, onto a single chip at an affordable price. Vena also offers the IEEE11073 standards for compatible exchange of information between health devices, and for this demonstration uses the medication monitor device specialisation. Cambridge Consultants is making Vena available as a reference design at a fixed price for clients to use as the basis for their own wireless healthcare device development, supported by design and development services as required.
Source
Cambridge Consultants
Visit our respiratory / asthma section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/149157.php>
APA
http://www.medicalnewstoday.com/releases/149157.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





